The gap between what politicians say about cannabis legalization and what the numbers actually show is growing wider - and harder to ignore. On the latest episode of the Trade To Black podcast, presented by Flowhub, hosts Shadd Dales and Anthony Varrell sat down with Flowhub CEO Kyle Sherman to unpack the disconnect across policy, enforcement, and technology. The conversation landed on a blunt conclusion: the dominant political narrative around cannabis and youth access doesn't hold up under scrutiny.

The Youth Access Myth, Measured Against Real Data

Sherman brought receipts. Between 2012 and 2025 - a period that encompasses the entire arc of state-level legalization - cannabis use among eighth, tenth, and twelfth graders declined significantly across all measured categories. That's not a marginal dip. It's a sustained, multi-grade trend running in the opposite direction from what prohibition advocates predict.

So why does the talking point persist? Sherman pointed to a specific culprit: lawmakers conflating licensed dispensaries, which operate under strict age-verification protocols, with unregulated hemp smoke shops. The hemp space, he argued, is where the real youth-access problem festers - storefronts selling products as potent as 2,000-milligram gummies with no age checks whatsoever. The irony is sharp. Regulated cannabis operators absorb reputational damage for a problem they didn't create and actively work to prevent.

Idaho, Breathalyzers, and the Long Arc of Reluctance

The podcast also covered Idaho, where lawmakers passed a resolution urging voters to reject a medical cannabis ballot measure. Sherman and the hosts weren't surprised - frustrated, yes, but not surprised. The comparison to alcohol prohibition holdouts was apt; some states didn't ratify the 21st Amendment until decades after repeal was a done deal. What eventually moves even the most resistant legislatures? Money. North Carolina's own estimate of $3 billion in foregone tax revenue offers a useful case study in how fiscal reality erodes ideological resistance.

Then there's the technology question. Sherman discussed a federally funded study exploring a 3D-printed roadside cannabis breathalyzer - a concept that sounds like progress until you examine the science underneath. THC metabolizes in the body in ways fundamentally different from alcohol. A person can test positive for THC metabolites days or weeks after consumption, long past any window of actual impairment. The alcohol breathalyzer, for all its apparent simplicity, took decades to move from invention to legal admissibility. Cannabis presents a harder problem by an order of magnitude. The hosts and Sherman agreed: the science isn't close to courtroom-ready.

What's Coming: Medicare, CBD, and a New Weekly Segment

Perhaps the most forward-looking moment in the episode was the preview of a new weekly Wednesday segment focused on the Medicare CBD pilot program. Dales and Varrell plan to bring on government officials, physicians, and insurance representatives to walk listeners through the initiative as it develops. That's a significant editorial commitment - and a signal that the intersection of cannabis, federal health programs, and insurance infrastructure is becoming too consequential to cover episodically.

The broader takeaway from this episode isn't complicated, but it matters: the data on youth access, the economics of legalization, the science of impairment testing - none of it aligns neatly with the political rhetoric that dominates statehouse floors. What you hear from the podium and what you find in the spreadsheet are two different things. And the distance between them isn't shrinking.